PureTech Health plc (LON:PRTC)
London · Delayed Price · Currency is GBP · Price in GBX 124.84
-0.76 (-0.60%)
Mar 5, 2026, 8:44 AM GMT
PureTech Health Employees
PureTech Health had 56 employees as of December 31, 2024. The number of employees decreased by 34 or -37.78% compared to the previous year.
Employees
56
Change (1Y)
-34
Growth (1Y)
-37.78%
Revenue / Employee
83.30K GBP
Profits / Employee
660.53K GBP
Market Cap
303.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 56 | -34 | -37.78% |
| Dec 31, 2023 | 90 | -21 | -18.92% |
| Dec 31, 2022 | 111 | 16 | 16.84% |
| Dec 31, 2021 | 95 | -155 | -62.00% |
| Dec 31, 2020 | 250 | -50 | -16.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genus | 3,190 |
| Oxford Nanopore Technologies | 1,325 |
| Oxford Biomedica | 900 |
| hVIVO | 301 |
| Avacta Group | 151 |
| 4basebio | 110 |
| Scancell Holdings | 60 |
| Faron Pharmaceuticals Oy | 32 |
PureTech Health News
- 8 days ago - PureTech to Present at the Leerink Partners Global Healthcare Conference - Business Wire
- 13 days ago - PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis - Business Wire
- 7 weeks ago - PureTech Health PLC at JPMorgan Healthcare Conference Transcript - GuruFocus
- 7 weeks ago - PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - PureTech Health (PRTC) Appoints Robert Lyne as CEO - GuruFocus
- 2 months ago - PureTech Health Appoints Robert Lyne As CEO; Focuses On Financing For Celea, Gallop Oncology - Nasdaq
- 2 months ago - PureTech Appoints Robert Lyne as Chief Executive Officer - Business Wire